Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies

Authors: Song Wen, Wei Zhou, Chun-ming Li, Juan Hu, Xiao-ming Hu, Ping Chen, Guo-liang Shao, Wu-hua Guo

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Despite the large number of published papers analyzing the prognostic role of Ki-67 in NSCLC, it is still not considered an established factor for routine use in clinical practice. The present meta-analysis summarizes and analyses the associations between Ki-67 expression and clinical outcome in NSCLC patients.

Methods

PubMed, Cochrane, and Embase databases were searched systematically using identical search strategies. The impacts of Ki-67 expression on survival in patients with NSCLC and NSCLC subtypes were evaluated. Furthermore, the association between Ki-67 expression and the clinicopathological features of NSCLC were evaluated.

Results

In total, 32 studies from 30 articles met the inclusion criteria, involving 5600 patients. Meta-analysis results suggested that high Ki-67 expression was negatively associated with overall survival (OS; HR = 1.59, 95 % CI 1.35-1.88, P < 0.001) and disease-free survival (DFS; HR = 2.21, 95 % CI 1.43-3.42, P < 0.001) in NSCLC patients. Analysis of the different subgroups of NSCLC suggested that the negative association between high Ki-67 expression and OS and DFS in Asian NSCLC patients was stronger than that in non-Asian NSCLC patients, particularly in early-stage (Stage I-II) adenocarcinoma (ADC) patients. Additionally, while high expression was more common in males, smokers, and those with poorer differentiation, there was no correlation between high Ki-67 expression and age or lymph node status. Importantly, significant correlations between high Ki-67 expression and clinicopathological features (males, higher tumor stage, poor differentiation) were seen only in Asian NSCLC patients.

Conclusions

The present meta-analysis indicated that elevated Ki-67 expression was associated with a poorer outcome in NSCLC patients, particularly in early-stage Asian ADC patients. Studies with larger numbers of patients are needed to validate our findings.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018–25.CrossRefPubMedPubMedCentral
3.
Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79:1–7.CrossRefPubMed
4.
Pugsley JM, Schmidt RA, Vesselle H. The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J. 2002;8:222–33.CrossRefPubMed
5.
Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, et al. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumor Biol. 2014;35:5735–40.CrossRef
6.
Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009;65:355–62.CrossRefPubMed
7.
Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, et al. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg. 2003;75:1727–32.CrossRefPubMed
8.
Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer. 2005;92:1231–9.CrossRefPubMedPubMedCentral
9.
Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742–8.CrossRefPubMedPubMedCentral
10.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(264–269):w264.CrossRef
11.
Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126–34.CrossRefPubMed
12.
Huang YJ, Qi WX, He AN, Sun YJ, Shen Z, Yao Y.Prognostic value of tissue vascular endothelial growth factor expression in bladder cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013;14:645–9.CrossRefPubMed
13.
He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153.
14.
Chen M, Huang J, Zhu Z, Zhang J, Li K. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer. 2013;13:539.CrossRefPubMedPubMedCentral
15.
Chen J, Zhao J, Ma R, Lin H, Liang X, Cai X. Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis. PLoS ONE. 2014;9:e103952.CrossRefPubMedPubMedCentral
16.
D'Amico TA, Aloia TA, Moore MB, Herndon JE 2nd, Brooks KR, Lau CL, et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000;69:882–6.
17.
Harpole Jr DH, Herndon 2nd JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995;55:51–6.PubMed
18.
Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol. 2009;16:3473–81.CrossRefPubMed
19.
Zhong X, Guan X, Liu W, Zhang L. Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer. Oncology Letters. 2014;8:1470–6.PubMedPubMedCentral
20.
van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 2000;89:160–6.CrossRefPubMed
21.
Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, et al. Clinical significance of KI67 expression in curatively resected non-small cell lung cancer. J Thorac Oncol. 2013;8:S1216–7.CrossRef
22.
Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res. 2004;10:7925–33.CrossRefPubMed
23.
Liu YZ, Jiang YY, Hao JJ, Lu SS, Zhang TT, Shang L, et al. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012;77:176–82.CrossRefPubMed
24.
Navaratnam S, Skliris G, Qing G, Banerji S, Badiani K, Tu D, et al. Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. Hormones and Cancer. 2012;3:93–100.CrossRefPubMed
25.
Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, et al. Biological prognostic factors for early stage completely resected non- small cell lung cancer. J Surg Oncol. 2000;74:53–60.CrossRefPubMed
26.
D'Amico TA1, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999;117:736–43.
27.
Demarchi LM, Reis MM, Palomino SA, Farhat C, Takagaki TY, Beyruti R, et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol. 2000;13:511–20.CrossRefPubMed
28.
Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Chiné S, et al. Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res. 1996;2:1067–75.PubMed
29.
Harpole Jr DH, Richards WG, Herndon 2nd JE, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg. 1996;61:1470–6.CrossRefPubMed
30.
Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T, et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer. 2001;34:59–65.CrossRefPubMed
31.
Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, et al. Prognostic significance of p27(KIP1) protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 2000;6:4073–81.PubMed
32.
Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 1997;80:1034–45.CrossRefPubMed
33.
Maddau C, Confortini M, Bisanzi S, Janni A, Montinaro F, Paci E, et al. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: Immunocytochemical detection with imprint cytology. Am J Clin Pathol. 2006;125:425–31.CrossRefPubMed
34.
Mehdi SA, Etzell JE, Newman NB, Weidner N, Kohman LJ, Graziano SL. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer. 1998;20:99–108.CrossRefPubMed
35.
Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer. 2002;38:51–7.CrossRefPubMed
36.
Nguyen VN, Mirejovsky P, Mirejovsky T, Melinova L, Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem. 2000;102:323–38.CrossRefPubMed
37.
Pence JC, Kerns BJM, Dodge RK, Iglehart JD. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg. 1993;128:1382–90.CrossRefPubMed
38.
Poleri C, Morero JL, Nieva B, Vázquez MF, Rodríguez C, de Titto E, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: Histopathologic and immunohistochemical analysis. Chest. 2003;123:1858–67.
39.
Puglisi F, Minisini AM, Aprile G, Barbone F, Cataldi P, Artico D, et al. Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer. Oncology. 2002;63:76–83.CrossRefPubMed
40.
Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol. 2001;19:4259–66.PubMed
41.
Shiba M, Kohno H, Kakizawa K, Iizasa T, Otsuji M, Saitoh Y, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer. 2000;89:1457–65.CrossRefPubMed
42.
Takahashi S, Kamata Y, Tamo W, Koyanagi M, Hatanaka R, Yamada Y, et al. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol. 2002;7:349–55.CrossRefPubMed
43.
Wu J, Zhou J, Yao L, Lang Y, Liang Y, Chen L, et al. High expression of M3 muscarinic acetylcholine receptor is a novel biomarker of poor prognostic in patients with non-small cell lung cancer. Tumor Biol. 2013;34:3939–44.CrossRef
44.
Yamashita S, Moroga T, Tokuishi K, Miyawaki M, Chujo M, Yamamoto S, et al. Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2011;17:341–6.CrossRefPubMed
45.
Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, Kim SH, et al. Immunohistochemical analysis of non-small cell lung cancer: Correlation with clinical parameters and prognosis. J Korean Med Sci. 2007;22:318–25.CrossRefPubMedPubMedCentral
46.
Zhong X, Guan X, Dong Q, Yang S, Liu W, Zhang L. Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis. Tumor Biol. 2014;35:7155–62.CrossRef
47.
Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer. 2014;111:1222–9.CrossRefPubMedPubMedCentral
48.
Tierney JFSL, Ghersi D. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:1–6.CrossRef
49.
Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol. 2009;380:169–77.CrossRefPubMed
50.
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 2004;22:2133–40.CrossRefPubMed
51.
Moldvay J. Personalized therapy in non-small cell lung cancer: from diagnosis to therapy. Orv Hetil. 2012;153:909–16.CrossRefPubMed
52.
Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol. 2009;4:1083–93.CrossRefPubMed
53.
Wang SJ, Fuller CD, Thomas Jr CR. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:180–90.CrossRefPubMed
Metadata
Title
Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies
Authors
Song Wen
Wei Zhou
Chun-ming Li
Juan Hu
Xiao-ming Hu
Ping Chen
Guo-liang Shao
Wu-hua Guo
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1524-2

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Study protocol

The patient-breast cancer care pathway: how could it be optimized?

Research article

Genome-wide association study of susceptibility loci for breast cancer in Sardinian population

Research article

The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer–a cross-sectional study of patient characteristics and cancer probability

Research article

Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression

Research article

eIF6 over-expression increases the motility and invasiveness of cancer cells by modulating the expression of a critical subset of membrane-bound proteins

Research article

The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits